**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71656

**Manuscript Type:** CASE REPORT

**Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports**

ZhangZ *et al*. Vedolizumab in treatment of ICPIs-induced colitis

Zhe Zhang, Chang-Qing Zheng

**Zhe Zhang, Chang-Qing Zheng,** The Second Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Author contributions:** Zhang Z reviewed the literature and contributed to the draft of the manuscript; Zheng CQ was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.

**Corresponding author: Chang-Qing Zheng, PhD, Doctor,** The Second Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang 110004, Liaoning Province, China. zhengchangqing88@163.com

**Received:** September 17, 2021

**Revised:** December 22, 2021

**Accepted:** September 7, 2022

**Published online:** October 16, 2022

**Abstract**

BACKGROUND

Immune check-point inhibitors-induced colitis (ICPIs-induced colitis) is one of the immune-related side effects. Steroids and Infliximab are commonly used to treat it. The patients of our report were treated by Vedolizumab.

CASE SUMMARY

The two patients went to the doctor with bloody stools and were treated by Sintilimab and Camrelizumab, respectively, for their malignant tumors. They were diagnosed as ICPIs-induced colitis based on endoscopic and histologic examination. The original immunotherapy was ceased while the anti-inflammatory therapy was introduced. The patients' colitis symptoms disappeared after the treatment and no recurrence was found during the follow-up period. The unique feature about the case reports is that Vedolizumab combined with short-term corticosteroids had achieved good therapeutic effects.

CONCLUSION

For the symptoms of bloody diarrhea after the ICPIs treatment of cancer, the possibility of ICPIs-induced colitis should be considered. Vedolizumab combined with short-term corticosteroids may be appropriate for the treatment.

**Key Words:** Immunotherapy; Colitis; Vedolizumab; Camrelizumab; Sintilimab; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang Z, Zheng CQ. Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. *World J Clin Cases* 2022; 10(29): 10550-10558

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i29/10550.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i29.10550

**Core Tip:** With its good efficacy, immunotherapy is increasingly being used in treating malignant tumors and attention shall be paid to the immune-related side effects caused by this therapy. This is a report on Sintilimab and Carrelizumab induced colitis which has rarely been reported in the past. Besides, a positive effect was achieved by adopting Vedolizumab combined with short-term corticosteroids therapy, which was different from the previous treatment.

**INTRODUCTION**

Immune check-point inhibitors (ICPIs) serve as a method of cancer immunotherapy. At present, multiple clinical trials of ICPIs present favorable response and survival rates in metastatic and various forms of malignancies. More indications are anticipated to be obtained for the application of ICPIs in cancer treatment in the future[[1,2]](applewebdata://FBB8E20F-AFE4-4A33-96E4-7E7E0ED4B708#OLE_LINK1). ICPIs usually result in the widespread activation of T-cells, so the nonspecific infiltration of these immune cells can virtually affect any organ system of the human body. For example, just one of the immune-related side effects is ICPIs-induced colitis[3,4].

Our Center has recently treated two patients with bloody and mucus stools. A 63-year-old woman received Sintilimab combined with Fluorouracil and Nedaplatin treatment for esophageal cancer. She had abdominal pain, mucus and bloody diarrhea 1 mo after the treatment. Another 69-year-old gentleman received Camrelizumab combined with Pemetrexed and Carboplatin for lung adenocarcinoma. He suffered bloody diarrhea 20 d after the treatment. Both cases were diagnosed as ICPIs-induced colitis based on the results of endoscopic and histologic examination. Terminating the immunotherapy and/or introducing anti-inflammatory therapy is the primary basis for handling high-grade immunotherapy induced-gastrointestinal (GI) adverse events[[5]](applewebdata://FBB8E20F-AFE4-4A33-96E4-7E7E0ED4B708#OLE_LINK3). Therefore, our two patients discontinued the immunotherapy for malignant tumors and received Vedolizumab combined with short-term corticosteroids injection therapy.

**CASE PRESENTATION**

***Chief complaints***

**Case 1:** A 63-year-old female went to the doctor in May 2021 with chief complaints of abdominal pain and bloody diarrhea accompanied by vomiting, fatigue, anorexia and weight loss of about 10 kg for 1 mo.

**Case 2:** A 69-year-old gentleman went to the doctor in March 2021. The chief complaint was bloody diarrhea, accompanied by abdominal pain, fatigue, tenesmus and weight loss of about 10 kg for 3 mo.

***History of present illness***

**Case 1:** The patient described that there had been mucus and blood in her bowel movements with the symptom of tenesmus 10-15 times per day for 1 mo.

**Case 2:** The patient suffered diarrhea 3 mo ago with a frequency up to 10 times a day. His stool was watery with a little blood and the symptoms did not worsen after taking montmorillonite powder and mesalazine orally. As he described, there had been mucus and more blood in his bowel movements 20-30 times per day for 1 mo and he also had fecal incontinence.

***History of past illness***

**Case 1:** The patient was diagnosed with esophageal squamous cell carcinoma 3 mo ago and treated with Sintilimab in combination with Fluorouracil and Nedaplatin. The symptoms of abdominal pain and bloody diarrhea appeared about 1 mo later after the treatment.

**Case 2:** The patient was diagnosed with poorly differentiated lung adenocarcinoma 4 mo ago which was anaplastic lymphoma kinase (-) and received treatment with Camrelizumab combined with Pemetrexed and Carboplatin. The symptoms of diarrhea appeared about 20 d after the treatment and then the patient received the immunotherapy for four cycles.

***Personal and family history***

**Cases 1 and 2:** The patient denied fever, chills, night sweats, skin rash, arthralgia, history of unclean diet, history of contact with those who had related diseases, recent travel history and no personal or family history of colitis.

***Physical examination***

**Case 1:** The patient's vital signs were stable. Physical examination results showed that the abdomen was flat, soft and tender without rebound pain or muscle tension. No skin rash or joint swelling was seen on the whole body.

**Case 2:** The patient's vital signs were stable. Physical examination results of the abdomen showed that the abdomen was flat, soft and there was generalized abdominal tenderness without rigidity. No skin rash or joint swelling was seen.

***Laboratory examinations***

**Case 1:** Initial significant laboratory results showed a hemoglobin level of 106 × 1012/L, leukocytes of 8.3 × 109/L and a platelet count of 349 × 109/L; other test results included a creatinine level of 68.4 μmol/L, blood urea of 4.65 mmol/L, alanine transaminase of 18 U/L, aspartate aminotransferase of 26 U/L, albumin of 24.2 g/L, C-reactive protein of 40.5 mg/L, serum potassium of 2.87 mmol/L, prothrombin time of 15.7 s and a d-dimer of 283 ug/L. Fecal pathogen culture, Clostridioides difficile, and Calprotectin tests didn’t show any detected positive results.

**Case 2:** Initial significant laboratory results included a hemoglobin level of 126 × 1012/L, leukocytes of 3.4 × 109/L and a platelet count of 367 × 109/L; other test results included a creatinine level of 79 μmol/L, blood urea of 7.68 mmol/L, alanine transaminase of 29 U/L, aspartate aminotransferase of 36 U/L, albumin of 33.2 g/L, C-reactive protein of 60.7 mg/L, Procalcitonin of 0.168 ng/mL, serum potassium of 3.51 mmol/L, prothrombin time of 10.9 s, and a d-dimer of 465 ug/L. Fecal pathogen culture, Clostridioides difficile and Calprotectin tests didn’t show any detected positive results.

***Imaging examinations***

**Case 1:** Abdominal computed tomography scan revealed inflammatory changes involving the thickened walls of the colon and rectum. After the enhanced scan, layered enhancement of the tube wall could be seen with exudation observed.

**Case 2:** Computed tomography (CT) scan of the abdomen revealed inflammatory changes involving thickened walls of the large intestine with blood vessels around the mesentery increased in size.

**MULTIDISCIPLINARY EXPERT CONSULTATION**

***Case 1***

The patient was examined by colonoscopy upon specialist consultation in Gastroenterology, Oncology and Infectious disease. According to the results of the colonoscopy, the mucosa at 20 cm of the distal ileum was smooth and there was marked hyperemia and edema of the mucosa from the ileocecum to the rectum. Diffuse mucosal erosion and superficial ulcers were visible and the mucosa was brittle and easy to bleed when exposed (Figure 1). HE staining biopsy showed no atypia of intestinal mucosal glands, but found slightly irregular crypt with branches, crypt inflammation and crypt abscess, infiltration of such inflammatory cells as interstitial neutrophils and plasma cells, acid-fast mycobacterium fluorescence staining, Epstein-Barr virus encoded RNA's in situ hybridization, cytomegalovirus immunohistochemistry (-) (Figure 2).

***Case 2***

The patient was examined by colonoscopy upon specialist consultation in Gastroenterology, Oncology and Infectious disease. Due to the narrow intestinal stenosis caused by obvious hyperemia and edema of the intestinal mucosa, the colonoscope could only reach the transverse colon proximal splenic flexion of the colon, but observed obvious hyperemia and edema in the colon and rectum mucosa with diffuse mucosal erosion, ulcers and bleeding. The ulcers were covered with white fur and the intestinal mucosa was brittle and prone to bleeding when exposed (Figure 3). HE staining biopsy showed crypt inflammation and crypt abscess, infiltration of inflammatory cells, acid-fast mycobacterium fluorescence staining, Epstein-Barr virus encoded RNA's in situ hybridization, cytomegalovirus immunohistochemistry (-) (Figure 4).

**FINAL DIAGNOSIS**

***Case 1***

Based on the history, imaging, endoscopic and histologic exams, the patient was diagnosed with grade IV colitis induced by immunotherapy.

***Case 2***

According to the history, imaging, endoscopic and histological examination, the patient was diagnosed with grade IV immune-mediated colitis.

**TREATMENT**

***Case 1***

On admission, Mesalazine was administered orally, somatostatin was pumped intravenously to inhibit intestinal juice secretion, and empiric antibiotic coverage with Cefmenoxime combined with Metronidazole was given. Upon the diagnosis of grade IV colitis, the patient received an intravenous infusion of 60 mg/d methylprednisolone for 7 d, after which corticosteroids were not used immediately. At the same time, 300 mg Vedolizumab was injected and 300 mg was given again after 2 wk.

***Case 2***

On admission, the patient underwent fasting, got parenteral nutrition and somatostatin injected to inhibit intestinal juice secretion and was empirically given Cefmenoxime and Metronidazole to control the infection. Upon the diagnosis of grade IV colitis, the patient received intravenous infusion of 60 mg/d of Methylprednisolone for 7 d and then corticosteroids were no longer administered immediately. At the same time, the patient was given 300 mg Vedolizumab intravenously and re-treated with 300 mg Vedolizumab at the 2nd and 4th week after the initial treatment with Vedolizumab.

**OUTCOME AND FOLLOW-UP**

***Case 1***

The 2nd day after the treatment, the stool frequency of the patient was reduced from 10-15 times a day to 4-5 times a day and the decrease of bloody stool was also significantly improved. The frequency of stool turned normal about 1 wk later after treatment. Currently, the patient has no abdominal pain or bloody diarrhea. The patient refused to undergo colonoscopy reexamination. The immunotherapy cycles were discontinued due to the colitis event. The patient is not currently continuing anti-tumor therapy for esophageal cancer.

***Case 2***

The patient's symptoms gradually improved after the treatment and the frequency of stool turned normal after 2 wk. The patient has no abdominal pain or bloody diarrhea right now. After 5 mo of treatment, the patient underwent colonoscopy, which showed visible mucosal erosion and a mucosal healing scar, and the hyperemia and edema of the colonic mucosa were less than before but still resulted in intestinal stenosis (Figure 5). Considering that the patient’s symptoms of hematochezia were relieved after treatment, the colonoscopy showed that intestinal mucosal erosion, ulcers and bleeding were alleviated but there were still symptoms of active colitis. 300 mg Vedolizumab was given intravenously, again. However, the immunotherapy cycles were discontinued due to the colitis. The patient is not currently continuing anti-tumor therapy for lung cancer.

**DISCUSSION**

It is proven that ICPIs are efficacious for treating cancers and improving the survival in metastatic malignancies[6]. ICPIs, by inhibiting checkpoints involved in regulating T-cell activation, enable augmentation of immunologic response against tumor cells which in turn has improved survival rates, particularly for patients with small cell lung carcinoma, renal cell carcinoma and melanoma[[1,](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK1)7,8]. ICPIs can cause a widespread activation of non-tumor-specific T-cells[[9]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK6). The disadvantage of this mechanism is the specific and uncontrolled activation of immune system cells which leads to excessive immune responses and autoimmune diseases. ICPIs also have an immune-mediated side-effect due to the action of aiding T-cell activation. The gastrointestinal (GI) tract, endocrine system, lungs, liver and skin are usually affected but GI tract Immune-Related Adverse Events (irAEs) typically presenting with diarrhea but are rarely affected. This could be either the only presenting symptom that is self-limiting or the part of ICPIs-induced colitis that requires hospitalization and treatment. The combination of CTLA-4 and PD-1 inhibitors resulted in a significantly higher incidence and severity of irAEs (including colitis) than single-agent PD-1 inhibition[[10]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK7).

As a humanized monoclonal antibody against PD-1, Camrelizumab (SHR-1210) usually blocks the binding of PD-1 to PD-L1 and consequently inhibits the immune escape of tumor cells. It has been shown by clinical trials of Phase 1 that Camrelizumab was well tolerated in patients with advanced solid tumors showing some antitumor activity[[11-14]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK8). In a phase-3 clinical study for the treatment of advanced esophageal squamous cell carcinoma, 228 patients who received Camrelizumab were reported, and 44 (19%) of patients were reported undergoing treatment-related to adverse events of grade 3 or higher, including three cases of diarrhea[[15]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK100). Of patients treated with Decitabine combined with Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma, 30% underwent immune-related AEs and 6% of them had diarrhea[[16]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK10). Lickliter *et al*[[17]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK11) found in a study of Camrelizumab for patients with advanced or metastatic cancer that a total of 6 patients reported 8 irAEs, including 1 with diarrhea (grade 3), and the results of the study suggested that there was no clear correlation between the incidence and severity of related irAEs and the dose of Camrelizumab.

As a fully human IgG4 monoclonal antibody, Sintilimab can bind to PD-1, block the interaction of PD-1 with its ligands and recover the anti-tumor response of T-cells. In addition, Sintilimab is undergoing the development of Phase I, II and III for various solid tumors including non-small cell lung cancer and esophageal cancer, in China[[18]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK12). The immune-related AEs of Sintilimab included diarrhea[[19]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK13) in the official instructions. In fact, ICPIs-colitis induced by Sintilimab were rarely reported. IrAEs, as autoimmune entities should be reversed by immunosuppression, with corticosteroids as the first-line agent[4]. Infliximab is usually reserved for treating GI-irAEs refractory to steroids or of high severity[[20]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK14). However, the antitumor efficacy of ICPIs therapy may be adversely affected by immunosuppressive therapy[[21]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK17). Furthermore, various debilitating adverse events including infections may occur because of systemic immunosuppressive therapy[[22]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK18).

Vedolizumab, a humanized monoclonal IgG1 antibody that selectively blocks gut lymphocyte trafficking by specifically recognizing the α4β7 integrin, is a cell surface glycoprotein variably expressed on T lymphocytes[[23](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK25),24]. The α4β7 integrin interacts with the mucosal addressin cell adhesion molecule on intestinal vasculature to regulate the migration of leukocytes into inflamed intestinal tissue[[25](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK26),[26](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK35)]. Vedolizumab is approved for the treatment of inflammatory bowel disease (IBD) because there are many similarities in the clinical manifestations including mucus and bloody diarrhea between ICPIs-induced colitis and IBD, and colonoscopy results show extensive and diffuse erosions and ulcers in the intestinal mucosa. Histology results suggest inflammatory cell infiltration, so the effective treatment for IBD may also be effective for ICPIs-induced colitis. Hamzah *et al*[[27]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK29) found in their study that Vedolizumab can be appropriate for the treatment of steroid-refractory ICPIs-induced colitis, with favorable outcomes and safety. Bergqvist *et al*[[28]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK29) had reported that the patients with ICPIs-induced colitis either steroid-refractory and/or steroid-dependent were given Vedolizumab treatment for two to four times, and most patients achieved steroid-free remission. Moreover, due to the gut-specific action mechanism of Vedolizumab, we speculate that the treatment for ICPIs-induced colitis may cause lesser affection on the treatment and development of cancer. However, due to the gradual effect of Vedolizumab[[29]](applewebdata://AF77BD33-283F-459C-9165-672570CE26DF#OLE_LINK29) and the fact that our two patients had severe bloody diarrhea, we chose the therapy of Vedolizumab combined with short-term corticosteroids. Fortunately, the patients underwent rapid remission of symptoms.

**CONCLUSION**

For the symptoms of bloody diarrhea after the ICPIs treatment of cancer, the possibility of ICPIs-induced colitis should be considered. Colonoscopy, mucosal biopsies, abdominal CT scan and fecal calprotectin are necessary for the diagnosis. Cessation of the immunotherapy and the introduction of anti-inflammatory therapy can help to control the ICPIs-induced colitis. Vedolizumab combined with short-term corticosteroids may be appropriate for the safe and effective treatment of ICPIs-induced colitis.

**REFERENCES**

1 **Herbst RS**, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 2014; **515**: 563-567 [PMID: 25428504 DOI: 10.1038/nature14011]

2 **Powles T**, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature* 2014; **515**: 558-562 [PMID: 25428503 DOI: 10.1038/nature13904]

3 **Michot JM**, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer* 2016; **54**: 139-148 [PMID: 26765102 DOI: 10.1016/j.ejca.2015.11.016]

4 **Haanen JBAG**, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017; **28**: iv119-iv142 [PMID: 28881921 DOI: 10.1093/annonc/mdx225]

5 **Karamchandani DM**, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. *J Clin Pathol* 2018; **71**: 665-671 [PMID: 29703758 DOI: 10.1136/jclinpath-2018-205143]

6 **Hodi FS**, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab *vs* ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 2016; **17**: 1558-1568 [PMID: 27622997 DOI: 10.1016/S1470-2045(16)30366-7]

7 **Webster RM**. The immune checkpoint inhibitors: where are we now? *Nat Rev Drug Discov* 2014; **13**: 883-884 [PMID: 25345674 DOI: 10.1038/nrd4476]

8 **Wang Y**, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. *J Immunother Cancer* 2018; **6**: 37 [PMID: 29747688 DOI: 10.1186/s40425-018-0346-6]

9 **Weber JS**, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012; **30**: 2691-2697 [PMID: 22614989 DOI: 10.1200/JCO.2012.41.6750]

10 **Larkin J**, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015; **373**: 23-34 [PMID: 26027431 DOI: 10.1056/NEJMoa1504030]

11 **Mo H**, Huang J, Xu J, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, Zhang H, Chi Y, Yang Q, Xu B. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. *Br J Cancer* 2018; **119**: 538-545 [PMID: 29755117 DOI: 10.1038/s41416-018-0100-3]

12 **Fang W**, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. *Lancet Oncol* 2018; **19**: 1338-1350 [PMID: 30213452 DOI: 10.1016/S1470-2045(18)30495-9]

13 **Huang J**, Xu B, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P, Zhang H, Yang Q, Jiao Y. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. *Clin Cancer Res* 2018; **24**: 1296-1304 [PMID: 29358502 DOI: 10.1158/1078-0432.CCR-17-2439]

14 **Xu J**, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. *Clin Cancer Res* 2019; **25**: 515-523 [PMID: 30348638 DOI: 10.1158/1078-0432.CCR-18-2484]

15 **Huang J**, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Camrelizumab *vs* investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol* 2020; **21**: 832-842 [PMID: 32416073 DOI: 10.1016/S1470-2045(20)30110-8]

16 **Nie J**, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. *J Clin Oncol* 2019; **37**: 1479-1489 [PMID: 31039052 DOI: 10.1200/JCO.18.02151]

17 **Lickliter JD**, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. *Drug Des Devel Ther* 2020; **14**: 1177-1189 [PMID: 32256049 DOI: 10.2147/DDDT.S243787]

18 **Hoy SM**. Sintilimab: First Global Approval. *Drugs* 2019; **79**: 341-346 [PMID: 30742278 DOI: 10.1007/s40265-019-1066-z]

19 Instructions for Sintilimab Injection (2020). Available from: http://inn-qc.iqiaomai.com/5c89f09e539a2.

20 **Johnson DH**, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. *J Immunother Cancer* 2018; **6**: 103 [PMID: 30305177 DOI: 10.1186/s40425-018-0412-0]

21 **Weber JS**, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *J Clin Oncol* 2017; **35**: 785-792 [PMID: 28068177 DOI: 10.1200/JCO.2015.66.1389]

22 **Waljee AK**, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. *BMJ* 2017; **357**: j1415 [PMID: 28404617 DOI: 10.1136/bmj.j1415]

23 **Feagan BG**, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013; **369**: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]

24 **Sandborn WJ**, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2013; **369**: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215739]

25 **Marsal J**, Agace WW. Targeting T-cell migration in inflammatory bowel disease. *J Intern Med* 2012; **272**: 411-429 [PMID: 22946654 DOI: 10.1111/j.1365-2796.2012.02588.x]

26 **Berlin C**, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. *Cell* 1993; **74**: 185-195 [PMID: 7687523 DOI: 10.1016/0092-8674(93)90305-a]

27 **Abu-Sbeih Hamzah**, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. *J Immunother Cancer* 2018; **6**: 142 [PMID: 30518410 DOI: 10.1186/s40425-018-0461-4]

28 **Bergqvist V**, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. *Cancer Immunol Immunother* 2017; **66**: 581-592 [PMID: 28204866 DOI: 10.1007/s00262-017-1962-6]

29 **Bryant RV**, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? *J Crohns Colitis* 2015; **9**: 356-366 [PMID: 25687206 DOI: 10.1093/ecco-jcc/jjv033]

**Footnotes**

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** Allthe authors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 17, 2021

**First decision:** December 9, 2021

**Article in press:** September 7, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Jabbarpour Z, Iran; Xu PF, China **A-Editor:** LiuX, China **S-Editor:** Xing YX **L-Editor:** Filipodia **P-Editor:** Xing YX

**Figure Legends**

****


**Figure 1 There was marked hyperemia and edema of the mucosa from ileocecum to rectum.** Diffuse mucosal erosion and superficial ulcers were visible and the mucosa was brittle and easy to bleed when exposed. A: Terminal ileum mucosa was normal; B: Erosion and superficial ulceration in ileocecal mucosa; C: Hyperemia, edema, erosion, and superficial ulceration in descending colon mucosa; D: Sigmoid colon mucosa is brittle and prone to bleeding.

****


**Figure 2 HE staining biopsy showed no atypia of intestinal mucosal glands but found slightly irregular crypt with branches, crypt inflammation and crypt abscess; infiltration of such inflammatory cells as interstitial neutrophils and plasma cells.** A: Low power view 10 × cryptitis; B: Medium power view 20 × cryptitis; C: Low power view 10 × crypt abscess; D: Medium power view 20 × crypt abscess.



**Figure 3 There were observed obvious hyperemia and edema in the colon and rectum mucosa and diffuse mucosal erosion, ulcers and bleeding.** The ulcers were covered with white fur and the intestinal mucosa was brittle and prone to bleeding when exposed. A: Mucosal erosion, ulceration and marked errhysis of transverse colon proximal splenic flexion of colon; B: Diffuse ulceration with white fur in descending colon mucosa; C: Erosion and superficial ulceration in sigmoid colon mucosa.

****

**Figure 4 HE staining biopsy showed crypt inflammation and crypt abscess, infiltration of inflammatory cells.** A: Low power view 10 × cryptitis; B: Medium power view 20 × cryptitis; C: Low power view 10 × crypt abscess; D: Medium power view 20 × crypt abscess.

****

**Figure 5 There were visible mucosal erosion and mucosal healing scars.** A: Mucosal healing scar in transverse colon proximal splenic flexion of colon and still narrow intestinal stenosis; B: Diffuse erosion in descending colon mucosa; C: Healing scar in sigmoid mucosa.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**